There are 119 resources available
15P - STELLAR-001: a phase 1 study of the anti-C5aR avdoralimab in combination with the anti-PD-L1 durvalumab in advanced solid tumors.
Presenter: Jaafar Bennouna
Session: e-Poster Display session
22P - Active immunization with a multi-peptide B cell vaccine, targeting Trastuzumab and Pertuzumab binding sites, prevents the formation of Her-2/neu expressing lung metastases
Presenter: Joshua Tobias
Session: e-Poster Display session
18P - Baseline and dynamic changes in haemoglobin levels predict treatment response and disease progression in metastatic renal cell carcinoma
Presenter: Yu-hsuen Yang
Session: e-Poster Display session
17P - Driving NK cell immunotherapy against NSCLC, in the context of hypoxia, using tri-specific engagers
Presenter: Jeffrey Miller
Session: e-Poster Display session
21P - Transcriptomic mapping of integrins and inmune activation in High- Grade Serous Ovarian Cancer.
Presenter: Katerin Rojas Laimito
Session: e-Poster Display session
16P - Checkpoint modification of BTLA-HVEM-LIGHT signaling by HSV-1 glycoprotein D (gD) improves vaccine-induced CD8+ T cell responses in pre-clinical cancer models
Presenter: Hildegund Ertl
Session: e-Poster Display session
19P - Tumor retargeting universal chimeric antigen receptor T cell (TRUE-CAR T) therapy in solid tumors
Presenter: Fanyan Meng
Session: e-Poster Display session
20P - Immuno-modulating effects of hyperthermia on PD-L1 and NLRC5 in ovarian cancer
Presenter: maha fezza
Session: e-Poster Display session
36P - A point mutation replacing Cysteine with Arginine at position 382 (C382R) in the transmembrane domain of FGFR2 leads to response to FGF2-inhibitor Pemigatinib in chemo-refractory intrahepatic cholangiocarcinoma
Presenter: louisa hempel
Session: e-Poster Display session
34P - Efficacy and toxicity analysis of Imatinib in Newly Diagnosed Patients of Chronic Myeloid Leukaemia: 18-years’ experience at a single large-volume centre.
Presenter: Rajan Yadav
Session: e-Poster Display session